Asia‑Pacific registry of mitral and tricuspid valve‑in‑valve and valve‑in‑ring procedures
The Asia-Pacific Mitral & Tricuspid Valve-in-Valve/Valve-in-Ring Registry (AP ViV Registry)
Collecting medical data from adults across the Asia‑Pacific who have had—or plan to have—mitral or tricuspid valve‑in‑valve or valve‑in‑ring procedures with a balloon‑expandable valve to see how patients do.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | National Heart Centre Singapore Academic / other |
| Locations | 8 sites (New Lambton Heights and 7 other locations) |
| Trial ID | NCT07058935 on ClinicalTrials.gov |
What this trial studies
This is a multicenter, observational cohort collecting both retrospective and prospective consecutive cases of transcatheter mitral and tricuspid valve‑in‑valve (ViV) and valve‑in‑ring (ViR) procedures performed with balloon‑expandable valves across participating Asia‑Pacific sites. Retrospective data include procedures from January 1, 2023 to the present, and prospective enrollment captures planned procedures going forward. Core clinical, procedural, and outcome data will be recorded to describe real‑world practice and patient outcomes. No investigational treatment is assigned and local investigators determine suitability for inclusion.
Who should consider this trial
Good fit: Adults aged 21 or older who have already undergone, or are scheduled to undergo, a mitral or tricuspid valve‑in‑valve or valve‑in‑ring procedure with a balloon‑expandable valve at a participating Asia‑Pacific site are eligible.
Not a fit: Patients with active endocarditis or other medical conditions that investigators deem unsuitable are excluded and unlikely to benefit from inclusion in the registry.
Why it matters
Potential benefit: If successful, the registry could provide real‑world outcome data that help clinicians refine patient selection and procedural planning for mitral or tricuspid ViV/ViR procedures.
How similar studies have performed: Other regional and international ViV/ViR registries have reported procedural feasibility and helped characterize outcomes, so this approach builds on existing, partly successful registry work rather than being wholly novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 21 2. Had at least one documented Mitral valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve/valve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve/valve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve/valve-in-ring procedure. (Prospective) Exclusion Criteria: 1. Active endocarditis 2. Any other conditions which investigator deems unsuitable for participation.
Where this trial is running
New Lambton Heights and 7 other locations
- John Hunter Hospital — New Lambton Heights, Australia (Not_yet_recruiting)
- Prince of Wales Hospital — Hong Kong, Hong Kong (Not_yet_recruiting)
- Queen Elizabeth Hospital — Hong Kong, Hong Kong (Not_yet_recruiting)
- MGM Healthcare Pvt Ltd — Chennai, Tamil Nadu, India (Not_yet_recruiting)
- The Madras Medical Mission — Chennai, Tamil Nadu, India (Not_yet_recruiting)
- Waikato Hospital — Hamilton, New Zealand (Not_yet_recruiting)
- National Heart Centre Singapore — Singapore, Singapore (Recruiting)
- Ramathibodi Hospital — Bangkok, Thailand (Not_yet_recruiting)
Study contacts
- Study coordinator: Deborah Yip
- Email: deborah.yip.x.y@singhealth.com.sg
- Phone: +65-67042301
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.